Ophthalmic drug delivery

Abstract

The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.

Description

RELATED APPLICATIONS[0001]The present application is a continuation of U.S. application Ser. No. 13 / 184,446, filed Jul. 15, 2011, now U.S. Pat. No. 9,087,145, which claims the benefit of the filing date of U.S. Provisional Application No. 61 / 400,864, filed Jul. 15, 2010, U.S. Provisional Application No. 61 / 401,850, filed Aug. 20, 2010, U.S. Provisional Application No. 61 / 401,920 filed Aug. 20, 2010, U.S. Provisional Application No. 61 / 401,918 filed Aug. 20, 2010, U.S. Provisional Application No. 61 / 401,848 filed Aug. 20, 2010, U.S. Provisional Application No. 61 / 401,849 filed Aug. 20, 2010, U.S. Provisional Application No. 61 / 462,576 filed Feb. 4, 2011, U.S. Provisional Application No. 61 / 462,791 filed Feb. 5, 2011, U.S. Provisional Application No. 61 / 463,280 filed Feb. 15, 2011, U.S. Provisional Application No. 61 / 516,462, filed Apr. 4, 2011, U.S. Provisional Application No. 61 / 516,496 filed Apr. 4, 2011, U.S. Provisional Application No. 61 / 516,495 filed Apr. 4, 2011, and U.S. Prov...

AI Technical Summary

Benefits of technology

The present patent relates to stable medicament compositions and methods for delivering them to the eye. Specifically, the patent provides a solution that involves delivering droplets containing the medicament with a specific size and ejecting velocity to the eye. The technical effects of the invention include improved delivery of medicament to the eye with reduced risk of wastage and improved efficacy. Additionally, the patent addresses the need for controlled droplet size and deposit parameters for the medicament solution, which can be adjusted based on the desired dosage and the characteristics of the subject in need.

Problems solved by technology

However, since the human eye can typically retain only 7 μl of fluid at a time, even a single medical droplet can result in overflow and loss of part of the medication from the eye.

Multiple drop dosage often compounds the problem of medication retention in the eye.

Subjects will typically administer all droplets required for a dosage in one sitting, which exacerbates the problem and can result in 50 to 90% of the medication overflowing and leaking out of the eye.

Another further problem is that a single droplet of the defined concentration marks the lower limit of a dose and, as such, the amount of active ingredient that can be administered at the defined concentration.